Nuvalent, Inc. (NUVL) NASDAQ
91.60
-1.415(-1.52%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
91.60
-1.415(-1.52%)
Currency In USD
Address
One Broadway
Cambridge, MA 02142
United States of America (the)
Phone
857 357 7000
Website
Sector
Healthcare
Industry
Biotechnology
Employees
162
First IPO Date
July 29, 2021
| Name | Title | Pay | Year Born |
| James R. Porter | Chief Executive Officer, President & Director | 1.14M | 1976 |
| Deborah Ann Miller | Chief Legal Officer & Secretary | 740,701 | 1976 |
| Darlene Noci | Chief Development Officer | 741,317 | 1978 |
| Alex Balcom | Chief Financial Officer & Treasurer | 753,791 | 1984 |
| Christopher D. Turner | Chief Medical Officer | 822,475 | 1969 |
| Matthew Metivier | Senior Vice President of Human Resources | 0 | N/A |
| Henry Pelish | Chief Scientific Officer | 0 | 1973 |
| Chelcie Lister | Senior Director of Investor Relations & Corporate Communications | 0 | N/A |
| John Soglia | Senior Vice President of Translational Development | 0 | N/A |
| Joshua Horan | Senior Vice President of Chemistry | 0 | N/A |
| Benjamin Lane | Chief Technical Operations Officer | 0 | N/A |
Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors, which is under Phase I development; and NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, central nervous system-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under Phase I/II clinical trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.